Galecto Drops Idiopathic Pulmonary Fibrosis Hopeful After Phase II Flop

Galecto’s investigational drug GB0139 fell short of its primary efficacy endpoint in the Phase IIb GALACTIC-1 trial, failing to slow the decline of forced vital capacity in patients with idiopathic pulmonary fibrosis, the company announced Tuesday.